Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis

Background: Pyrotinib, an irreversible pan-ERBB inhibitor, has shown promising antitumour activity, and acceptable tolerability. This research was conducted to evaluate the actual use and effectiveness of pyrotinib in China, therefore, contributed to solve the problem of real-world data scarcity. Me...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Qitong, Ouyang, Dengjie, Anwar, Munawar, Xie, Ning, Wang, Shouman, Fan, Peizhi, Qian, Liyuan, Chen, Gannong, Zhou, Enxiang, Guo, Lei, Gu, Xiaowen, Ding, Boni, Yang, Xiaohong, Liu, Liping, Deng, Chao, Xiao, Zhi, Li, Jing, Wang, Yunqi, Zeng, Shan, Hu, Jinhui, Zhou, Wei, Qiu, Bo, Wang, Zhongming, Weng, Jie, Liu, Mingwen, Li, Yi, Tang, Tiegang, Wang, Jianguo, Zhang, Hui, Dai, Bin, Tang, Wuping, Wu, Tao, Xiao, Maoliang, Li, Xiantao, Liu, Hailong, Li, Lai, Yi, Wenjun, Ouyang, Quchang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263174/
https://www.ncbi.nlm.nih.gov/pubmed/32528890
http://dx.doi.org/10.3389/fonc.2020.00811

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263174/
https://www.ncbi.nlm.nih.gov/pubmed/32528890
http://dx.doi.org/10.3389/fonc.2020.00811

Ejemplares similares